^
Association details:
| Biomarker: | HER-2 L755S |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer
Excerpt:
...G309E, S310F, S310Y, S653C, V659E, R678Q, V697L, T733I, L755S, L755P, E757A, D769H, D769Y, D769N, G776V, G776C, V777L, L841V, V842I, R849W, L869R, R896C); insertions/deletions (A775_G776insYVMA aka Y772_A755dup, G776VinsC, G776AinsVGC, G776 insertions, G778_S779insCPG, P780_781insGSP aka G778_P780dup, L755_T759del) and/or HER3 activating mutations; there is...
Trial ID:
Source:
Title:
HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2- positive breast cancer cell models
Published date:
11/17/2020
Excerpt:
RNA-seq analysis revealed the presence of HER2 L755S mutation in the LapR and NrbR derivatives, but not in P cells...HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2- positive breast cancer cell models...On the other hand, the resistant derivatives were cross-resistant to Tuca, both as a single-agent and in combination with T.
Source:
Title:
Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Excerpt:
CONTRADICTING EVIDENCE: In contrast, neratinib produced a strong inhibition of colony formation for all eight mutations, including K753E and L755S.
DOI:
10.1158/1078-0432.CCR-15-3036
